Yttrium-90 radioembolization of unresectable hepatocellular carcinoma – a single center experience

References

• BoschFXRibesJDíazMClériesRPrimary liver cancer: worldwide incidence and trendsGastroenterology20041275 Suppl 1S5S1615508102
   PubMed Web of Science ®Google Scholar
• LlovetJMDucreuxMEuropean Association For The Study Of The Liver; European Organization For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinomaJ Hepatol201256490894322424438
   PubMed Web of Science ®Google Scholar
• LencioniRCioniDCrocettiLEarly-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablationRadiology2005234396196715665226
   PubMed Web of Science ®Google Scholar
• BruixJShermanMPractice Guidelines Committee, American Association for the Study of Liver DiseasesManagement of hepatocellular carcinomaHepatology20054251208123616250051
   PubMed Web of Science ®Google Scholar
• ElnekaveEErinjeriJPBrownKTLong-term outcomes comparing surgery to embolization-ablation for treatment of solitary HCC<7 cmAnn Surg Oncol20132092881288623563960
   PubMed Web of Science ®Google Scholar
• ZhaoMWangJPPanCCCT-guided radiofrequency ablation after with transarterial chemoembolization in treating unresectable hepatocellular carcinoma with long overall survivalimprovementEur J Radiol201281102717272522245655
   PubMed Web of Science ®Google Scholar
• VeltriAMorettoPDoriguzziAPaganoECarraraGGandiniGRadiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC)Eur Radiol200616366166916228211
   PubMed Web of Science ®Google Scholar
• KagawaTKoizumiJKojimaSTokai RFA Study GroupTranscatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: comparison with surgical resectionCancer2010116153638364420564097
   PubMed Web of Science ®Google Scholar
• MalagariKPomoniMKelekisAProspective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinomaCardiovasc Intervent Radiol201033354155119937027
   PubMed Web of Science ®Google Scholar
• GolfieriRGiampalmaERenzulliMRandomized controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinomaBr J Cancer2014111225526424937669
   PubMed Web of Science ®Google Scholar
• LlovetJMRealMIMontañaXArterial embolisation or chemoembolisation vs symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trialLancet200235993191734173912049862
   PubMed Web of Science ®Google Scholar
• LlovetJMRicciSMazzaferroVSHARP Investigators Study GroupSorafenib in advanced hepatocellular carcinomaN Engl J Med2008359437839018650514
   PubMed Web of Science ®Google Scholar
• ChengALKangYKChenZEfficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trialLancet Oncol2009101253419095497
   PubMed Web of Science ®Google Scholar
• LiYGaoZHQuXJThe adverse effects of sorafenib in patients with advanced cancersBasic Clin Pharmacol Toxicol2015116321622125495944
   PubMedGoogle Scholar
• LlovetJMBustamanteJCastellsANatural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trialsHepatology199929162679862851
   PubMed Web of Science ®Google Scholar
• MinagawaMMakuuchiMTreatment of hepatocellular carcinoma accompanied by portal vein tumor thrombusWorld J Gastroenterol200612477561756717171782
   PubMed Web of Science ®Google Scholar
• Schöniger-HekeleMMüllerCKutilekMOesterreicherCFerenciPGanglAHepatocellular carcinoma in Central Europe: prognostic features and survivalGut200148110310911115830
   PubMed Web of Science ®Google Scholar
• SalemRMazzaferroVSangroBYttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectivesHepatology20135862188219723512791
   PubMed Web of Science ®Google Scholar
• SalemRGordonACMouliSY90 Radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinomaGastroenterology2016151611551163.e227575820
   PubMed Web of Science ®Google Scholar
• SalemRThurstonKGRadioembolization with 90Yttrium micro-spheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerationsJ Vasc Interv Radiol20061781251127816923973
   PubMed Web of Science ®Google Scholar
• KennedyANagSSalemRRecommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortiumInt J Radiat Oncol Biol Phys2007681132317448867
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The LiverEuropean Organization For Research And Treatment Of CancerEASL-EORTC clinical practice guidelines: management of hepatocellular carcinomaJ Hepatol201256490894322424438
   PubMed Web of Science ®Google Scholar
• MahnkenAHSpreaficoCMaleuxGHelmbergerTJakobsTFStandards of practice in transarterial radioembolizationCardiovasc Intervent Radiol201336361362223511991
   PubMed Web of Science ®Google Scholar
• LencioniRLlovetJMModified RECIST (mRECIST) assessment for hepatocellular carcinomaSemin Liver Dis2010301526020175033
   PubMed Web of Science ®Google Scholar
• RaoulJLGilabertMPianaGHow to define transarterial chemoembolization failure or refractoriness: a European perspectiveLiver Cancer20143211912424945002
   PubMed Web of Science ®Google Scholar
• Peck-RadosavljevicMDrug therapy for advanced-stage liver cancerLiver Cancer20143212513124945003
   PubMedGoogle Scholar
• KudoMBiomarkers and personalized sorafenib therapyLiver Cancer201433–439940426280001
   PubMedGoogle Scholar
• FornerAGilabertMBruixJRaoulJLTreatment of intermediate-stage hepatocellular carcinomaNat Rev Clin Oncol201411952553525091611
   PubMed Web of Science ®Google Scholar
• UkaKAikataHTakakiSClinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinomaWorld J Gastroenterol200713341442017230611
   PubMed Web of Science ®Google Scholar
• HilgardPHamamiMFoulyAERadioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survivalHepatology20105251741174921038413
   PubMed Web of Science ®Google Scholar
• SangroBCarpaneseLCianniREuropean Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY)Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluationHepatology201154386887821618574
   PubMed Web of Science ®Google Scholar
• SalemRLewandowskiRJMulcahyMFRadioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomesGastroenterology20101381526419766639
   PubMed Web of Science ®Google Scholar
• IñarrairaeguiMMartinez-CuestaARodríguezMAnalysis of prognostic factors after yttrium-90 radioembolization of advanced hepatocellular carcinomaInt J Radiat Oncol Biol Phys20107751441144820056355
   PubMed Web of Science ®Google Scholar
• KulikLMCarrBIMulcahyMFSafety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosisHepatology2008471718118027884
   PubMed Web of Science ®Google Scholar
• GianniniEGFarinatiFCiccareseFItalian Liver Cancer (ITA.LI.CA) groupPrognosis of untreated hepatocellular carcinomaHepatology201561118419025234419
   PubMed Web of Science ®Google Scholar
• ZhangYLiYJiHZhaoXLuHTransarterial Y90 radioembolization vs chemoembolization for patients with hepatocellular carcinoma: a meta-analysisBiosci Trends20159528929826559021
   PubMedGoogle Scholar
• LauWYSangroBChenPJTreatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90Oncology201384531131823615394
   PubMed Web of Science ®Google Scholar
• LauWYHoSLeungTWSelective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheresInt J Radiat Oncol Biol Phys19984035835929486608
   PubMed Web of Science ®Google Scholar
• SangroBBilbaoJIBoanJRadioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinomaInt J Radiat Oncol Biol Phys200666379280016904840
   PubMed Web of Science ®Google Scholar
• SangroBIñarrairaeguiMBilbaoJIRadioembolization for hepatocel-lular carcinomaJ Hepatol201256246447321816126
   PubMed Web of Science ®Google Scholar
• RiazAKulikLLewandowskiRJRadiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheresHepatology20094941185119319133645
   PubMed Web of Science ®Google Scholar
• VilgrainVBouattourMSibertASARAH: a randomized controlled trial comparing efficacy and safety of selective internal radiation therapy (with yttrium-90 microspheres) and sorafenib in patients with locally advanced hepatocellular carcinoma. The International Liver Congress™ 2017 52nd Annual Meeting of the European Association for the Study of the LiverJ Hepatol201766Suppl 1 Abs GS-012
   Google Scholar
• ChowPKHGandhiMPhase III multi-center open-label randomized controlled trial of selective internal radiation therapy (SIRT) versus sorafenib in locally advanced hepatocellular carcinoma: The SIRveNIB study. 2017. ASCO Annual MeetingJ Clin Oncol20173535 Abs 4002
   Google Scholar
• BruixJShermanMAmerican Association for the Study of Liver DiseasesManagement of hepatocellular carcinoma: an updateHepatology20115331020102221374666
   PubMed Web of Science ®Google Scholar
• WoodallCEScogginsCREllisSFIs selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis?J Am Coll Surg2009208337538219317999
   PubMed Web of Science ®Google Scholar
• GoinJESalemRCarrBITreatment of unresectable hepato-cellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicitiesJ Vasc Interv Radiol2005162 Pt 120521315713921
   PubMedGoogle Scholar
• SalemRLewandowskiRJAtassiBTreatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survivalJ Vasc Interv Radiol200516121627163916371529
   PubMed Web of Science ®Google Scholar
• ChenSWLinLCKuoYCLiangJAKuoCCChiouJFPhase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinomaInt J Radiat Oncol Biol Phys20148851041104724661657
   PubMed Web of Science ®Google Scholar
• RiazALewandowskiRJKulikLMComplications following radioembolization with yttrium-90 microspheres: a comprehensive literature reviewJ Vasc Interv Radiol20092091121113019640737
   PubMed Web of Science ®Google Scholar
• LamMGBanerjeeSLouieJDRoot cause analysis of gastroduodenal ulceration after yttrium-90 radioembolizationCardiovasc Intervent Radiol20133661536154723435742
   PubMedGoogle Scholar
• PieperCCWillinekWAThomasDIncidence and risk factors of early arterial blood flow stasis during first radioembolization of primary and secondary liver malignancy using resin microspheres: an initial single-center analysisEur Radiol20162682779278926560720
   PubMedGoogle Scholar
• EdelineJGilabertMGarinEBoucherERaoulJLYttrium-90 microsphere radioembolization for hepatocellular carcinomaLiver Cancer201541162526020026
   PubMedGoogle Scholar
• FuruseJIshiiHNagaseMKawashimaMOginoTYoshinoMAdverse hepatic events caused by radiotherapy for advanced hepatocellular carcinomaJ Gastroenterol Hepatol200520101512151816174067
   PubMedGoogle Scholar
• SeidenstickerRSeidenstickerMDammRHepatic toxicity after radioembolization of the liver using (90)Y-microspheres: sequential lobar versus hole liver approachCardiovasc Intervent Radiol20123551109111822037709
   PubMedGoogle Scholar